jetcityimage/iStock Editorial via Getty Images
Swedish biotech AlzeCure Pharma announced on Tuesday a collaboration and a licensing agreement with Eli Lilly (LLY) to develop an Alzheimer’s therapy as part of a deal that could potentially exceed $1B.
Per the terms, the U.S. drugmaker will receive global rights
